|
|
Background: Anxiety and depressive disorders (ADD) significantly increase functional limitations in patients with rheumatoid arthritis (RA). Successful psychopharmacotherapy (PPT) of ADD can potentially improve the functional abilities of RA-patients.
Objectives: To compare changes in functional disability of RA patients with comorbid ADD treated with conventional disease-modifying antirheumatic drugs (cDMARDs) alone or in combination with biologic DMARDs (bDMARDs) and/or PPT.
Methods: 128 RA-patients (pts) were enrolled, 86% were women with a mean age of 47,4±11,3 (M±SD) yrs. All patients met the full ACR/EULAR 2010 criteria for RA. Functional limitations were assessed using Health Assessment Questionnaire (HAQ), mean HAQ was 1,42±0,78 at baseline. 69,4% RA-pts were already taking prednisone (9 [5; 10] mg/day (Me (25%; 75%)), 84,4% - cDMARDs, 7,8% - bDMARDs (anti-TNF-α – 6,3%, rituximab – 1,6%). ADD were diagnosed by psychiatrist in 123 (96,1%) of RA-pts in accordance with ICD-1
|
Скачать файл
